TRUSTEES OF INDIANA UNIVERSITY
Documentation of cardiomyocyte cell cycle activity and myocardial tissue regeneration typically requires extensive histochemical processing and frequently relies on the use of subjective criteria for cell lineage determination. Although reporter transgenes can greatly assist such analyses, their use also requires considerable tissue processing, and current transgenic reporter systems do not readily permit monitoring of cumulative regenerative growth. The studies proposed in this R21 application will generate transgenic reporter models which can be used to quantitate cardiomyocyte cell cycle activity and cumulative myocardial regeneration with minimal tissue processing. Aim 1 will utilize a cardiomyocyte-restricted promoter to target expression of a fusion between proteins with intrinsic fluorescent activity and proteins which undergo cell cycle- dependent changes in sub-nuclear localization. Cardiomyocyte cell cycle status can be quantitated simply by monitoring the pattern of reporter protein epifluorescence within the nucleus. Aim 2 will develop a tertiary transgenic reporter system to quantitate cumulative de novo myocardial growth in adult hearts. The system will utilize an existing conditional Cre-recombinase transgenic model, in combination with two new conditional transgenes, to permanently activate a nuclear localized EGFP reporter protein in all adult cardiomyocytes undergoing de novo proliferation. Consequently, cumulative myocardial growth resulting from cardiomyocyte proliferation can be determined simply by scoring the number of cells with nuclear EGFP epifluorescence. We will utilize existing transgenic models that exhibit enhanced cardiomyocyte proliferation to validate both reporter gene systems. Once validated, we will develop automated data acquisition and analyses protocols. The reporter transgenes proposed in this application will have the distinct advantage over existing models in that data can be acquired with minimal sample processing (in essence, requiring only tissue fixation and sectioning). Moreover, the systems will permit quantitation of cumulative regenerative growth, which cannot easily be determined with existing models. The use of automated techniques for data acquisition and analysis should permit precise quantitation of low-frequency events, and the use of fluorescent reporters will permit analyses in living tissue.
Choose a quarter and click "Go."
| AWARD OVERVIEW |
| Award Number |
1R21HL091189-01 |
Funding Agency |
Department of Health and Human Services |
| Total Award Amount |
$423,500 |
Project Location - City |
INDIANAPOLIS |
| Award Date |
05/15/2009 |
Project Location - State |
IN |
| Project Status |
Completed |
Project Location - Zip |
46202-1000
|
| Jobs Reported |
0.00 |
Congressional District |
07 |
| Project Location - Country |
US |
|
|
Recipient Information
(Grants)
| Recipient Information (Grants) |
|
Recipient Name
|
TRUSTEES OF INDIANA UNIVERSITY |
| Recipient DUNS Number |
603007902
|
| Recipient Address |
620 UNION DR RM 618 |
| Recipient City |
INDIANAPOLIS |
| Recipient State |
Indiana |
| Recipient Zip |
46202-5130 |
| Recipient Congressional District |
07 |
| Recipient Country |
USA |
Required to Report Top 5 Highly Compensated Officials |
No |
Projects and Jobs Information
| Projects and Jobs Information |
| Project Title |
Transgenic Reporters for Cardiac Growth and Regeneration |
| Project Status |
Completed |
| Final Project Report Submitted |
Yes |
| Project Activities Description |
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) |
| Quarterly Activities/Project Description |
The studies proposed in this R21 application will generate transgenic reporter models which can be used to quantitate cardiomyocyte cell cycle activity and cumulative myocardial regeneration with minimal tissue processing. Aim 1 will utilize a cardiomyocyte-restricted promoter to target expression of a fusion between proteins with intrinsic fluorescent activity and proteins which undergo cell cycle- dependent changes in sub-nuclear localization. Cardiomyocyte cell cycle status can be quantitated simply by monitoring the pattern of reporter protein epifluorescence within the nucleus. We have generated the initial series of transgenic reporter animals. The reporters exhibited good penetrance, however the fusion gene itself resulted in an impact on cell cycle activity. We re-engineered the construct such that it comprises the fluorescent reporter and sequences responsible for nuclear translocation only, and have started to generate new mice. Validation experiments are in progress. Aim 2 will develop a transgenic reporter system to detect cumulative de novo myocardial growth in adult hearts. The system will utilize an existing conditional Cre-recombinase transgenic model, in combination with two new conditional transgenes, to activate an EGFP reporter protein in all adult cardiomyocytes undergoing de novo proliferation. We generated the initial mice, and while base-line expression was good, cre-mediated recombination resulted in a loss of expression. We believe that this reflects integration of an incomplete 3’ concatenate in the transgenic mice, which upon cre-mediated recombination results in the generation of an incomplete transcriptional unit. To circumvent this problem, we have generated a targeting vector to deliver a single copy of the reporter into the thymidine kinase locus; this strategy should eliminate the loss of expression upon recombination. Work is complete and the remaining balance of award will be returned to NIH. |
| Jobs Created |
0.00 |
| Description of Jobs Created |
No jobs created/retained |
Purchaser Information
(Grants)
| Purchaser Information |
| Contracting Office ID |
Not Reported |
| Contracting Office Name |
Not Available |
| Contracting Office Region |
Not Available |
| TAS Major Program |
75-0871 |
| Award Information |
| Award Date |
05/15/2009 |
| Award Number |
1R21HL091189-01 |
| Order Number |
|
| Award Type |
Grants |
| Funding Agency ID |
75 |
| Funding Agency Name |
Department of Health and Human Services |
| Funding Office Name |
Not Available |
| Awarding Agency ID |
75 |
| Awarding Agency Name |
Department of Health and Human Services |
| Amount of Award |
$423,500 |
| Funds Invoiced/Received |
$420,465 |
| Expenditure Amount |
$420,465 |
| Infrastructure Expenditure Amount |
$0 |
| Infrastructure Purpose and Rationale |
Not Reported |
| Infrastructure Point of Contact Name |
Not Reported |
| Infrastructure Point of Contact Email |
Not Reported |
| Infrastructure Point of Contact Phone |
Not Reported |
| Infrastructure Point of Contact Address |
Not Reported |
| Infrastructure Point of Contact City |
Not Reported |
| Infrastructure Point of Contact State |
Not Reported |
| Infrastructure Point of Contact Zip |
Not Reported |
Product or Service Information
(Grants)
| Product or Service Information |
| Primary Activity Code |
541712 |
| Activity Description |
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) |
| Sub-Awards Information |
| Sub-awards to Organizations |
0 |
| Sub-award Amounts to Organizations |
$0 |
| Sub-Awards to Individuals |
0 |
| Sub-Award Amounts to Individuals |
$0 |
| Number of Sub-awards less than $25,000/award |
0 |
| Amount of Sub-awards less than $25,000/award |
$0 |
| Number of payments to vendors greater than $25,000 |
0 |
| Total Amount of payments to vendors greater than $25,000/award |
$0 |
| Number of payments to vendors less than $25,000/award |
20 |
| Total Amount of payments to vendors less than $25,000/award |
$17,019 |
| Location Information |
| Latitude, Longitude |
39º 47' 43",
-86º 11' 14" |
| Congressional District |
07 |
| Address 1 |
RG 4100 TB:CARD, |
| Address 2 |
|
| City |
INDIANAPOLIS |
| County |
Marion |
| State |
IN |
| Zip |
46202-1000 |
|
|